William Spear, MD
Clinical Cardiac Electrophysiology · Evergreen Park, ILNPI 1811085889
Payments from drug & device makers
Across 829 payments — averaging $814.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$468K
- Atricure, Inc.$97K
- Abbott$28K
- Biosense Webster, Inc.$24K
- Johnson & Johnson$20K
- Cardiva Medical, Inc.$12K
- plus $26K from 30 others
What the payments were for
- Consulting fees$37,32330%
- Speaking & faculty fees$54,51644%
- Travel & lodging$12,99310%
- Food & beverage$20,34616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 303 | $468,174 |
| Atricure, Inc. | 29 | $96,683 |
| Abbott | 62 | $27,544 |
| Biosense Webster, Inc. | 44 | $24,268 |
| Johnson & Johnson | 121 | $19,965 |
| Cardiva Medical, Inc. | 10 | $12,175 |
| Stereotaxis Inc | 2 | $7,434 |
| Medtronic(2 entities) | 62 | $4,445 |
| E.r. Squibb & Sons, L.L.C. | 41 | $4,422 |
| Medical Device Business Services, Inc. | 5 | $2,889 |
| Pfizer | 19 | $2,632 |
| Volta Medical Inc | 3 | $1,676 |
| Boehringer Ingelheim | 17 | $327 |
| Novo Nordisk | 10 | $298 |
| Sanofi-aventis U.S. LLC | 18 | $284 |
| Novartis | 16 | $280 |
| Edwards Lifesciences | 4 | $256 |
| AstraZeneca | 14 | $249 |
| AOP Health US, LLC | 1 | $174 |
| Amgen | 6 | $160 |
| Actelion Pharmaceuticals US, Inc. | 5 | $127 |
| Preventice Services, LLC | 1 | $104 |
| Merck | 6 | $100 |
| Scpharmaceuticals Inc. | 4 | $85 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $63 |
| Elutia, Inc. | 7 | $53 |
| Alnylam Pharmaceuticals Inc. | 2 | $49 |
| Philips North America LLC | 2 | $45 |
| Lundbeck LLC | 3 | $39 |
| Terumo Medical Corporation | 2 | $30 |
| Bridgebio Pharma, Inc. | 1 | $29 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Cordis US CORP. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Jubilant Draximage Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL EP$29,375
- XARELTO$18,377
- GENERAL - THERAPIES$14,542
- Carto 3$9,836
- ELIQUIS$6,107
- AMPLATZER TALISMAN$2,334
- Watchman$2,072
- VX1$1,676
- WATCHMAN FLX$1,401
- AMPLATZER AMULET$941
- WATCHMAN Access System$595
- LINQ II$436
- Micra$419
- ENSITE$408
- Niobe$404
- Rapiblyk$348
- ENSITE PRECISION$334
- Rhythmia Mapping System$313
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$277
- QDOT MICRO Catheter$234
How this compares
$675,134 in reported general payments places this provider in the 90th percentile of 158 clinical cardiac electrophysiology providers in Illinois.
See all clinical cardiac electrophysiology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 690 | $691,878 |
| XareltoRivaroxaban | 215 | $223,623 |
| EntrestoSacubitril/Valsartan | 130 | $134,743 |
| MultaqDronedarone Hcl | 48 | $81,533 |
| Flecainide Acetate | 442 | $19,720 |
| Metoprolol Succinate | 664 | $9,867 |
| Propafenone Hcl ErPropafenone Hcl | 12 | $3,885 |
| Amiodarone Hcl | 156 | $3,286 |
| Losartan Potassium | 275 | $2,906 |
| Nebivolol Hcl | 35 | $2,647 |
| Potassium Chloride | 109 | $2,211 |
| Atorvastatin Calcium | 164 | $1,863 |
| Carvedilol | 170 | $1,715 |
| Metoprolol Tartrate | 159 | $1,636 |
| Furosemide | 270 | $1,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $2,632 | $691,878690 claims |
| Johnson & JohnsonXarelto | $19,965 | $223,623215 claims |
| NovartisEntresto | $280 | $134,743130 claims |
| Sanofi-aventis U.S. LLCMultaq | $284 | $81,53348 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 158 clinical cardiac electrophysiology providers in Illinois.
Other clinical cardiac electrophysiology in Evergreen Park
- Roderick TungChicago$2.3M
- Bradley KnightChicago$1.6M
- Mark MetzlEvanston$1.5M
- Moeen SaleemNaperville$1.2M
- Ziad IssaSpringfield$1.2M
- Henry HuangGeneva$955K
- Mansour RazminiaPalos Heights$930K
- Gaurav UpadhyayChicago$785K
- Kousik KrishnanNaperville$517K
- Albert LinChicago$486K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.